Evidence map›Paper›PMID 27440980›Full record

ArticleEthnicity & disease2016

A Global Perspective on Using Implementation Research to Address Hypertension-Associated Target Organ Damage.

Emmanuel Peprah, Maria Lopez-Class, Susan Shero, Joylene John-Sowah, Michael Engelgau

Abstract read
In one paragraph

Article in Ethnicity & disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Reducing major risk factors for chronic kidney disease.Kidney international supplements · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Emmanuel PeprahCenter for Translation Research and Implementation Science, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda MD.
Maria Lopez-ClassCenter for Translation Research and Implementation Science, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda MD.
Susan SheroCenter for Translation Research and Implementation Science, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda MD.
Joylene John-SowahCenter for Translation Research and Implementation Science, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda MD.
Michael EngelgauCenter for Translation Research and Implementation Science, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda MD.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertension, a major risk factor for cardiovascular disease, imposes a significant public health burden and challenge to address it worldwide. Scaling up delivery of proven, effective interventions for hypertension could significantly advance the goal of reducing the global burden. Although significant progress has been made in many countries, some lament that large-scale initiatives focused on reducing blood pressure in global populations have not effectively addressed this challenge. Late-stage implementation research plays a critical role in determining effective and sustainable scale-up of these initiatives. In this article, we briefly discuss some of the global initiatives that have been funded by the National Heart, Lung, and Blood Institute of the US National Institutes of Health. Intervention delivery strategies in low resource settings must have demonstrated effectiveness and consideration for the social, cultural and physical context (eg, access, affordability, and availability of medications) in which a program is being delivered in order to be sustainable nationally and globally. Hence, the use of implementation research is central to determining sustainable delivery of evidence-based and tailored interventions focused on hypertension control. The sustained control of hypertension in global populations holds tremendous potential for reducing morbidity, premature mortality, and the adverse economic impact of cardiovascular disease in all regions.

Indexed as

Global HealthCardiovascular DiseasesHumansHypertensionPublic HealthResearch PersonnelRisk FactorsGlobal HealthHypertensionImplementation ResearchTarget Organ Damage

Identifiers

PMID27440980
PMCPMC4948807

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.